AstraZeneca Showcases Commitment to High-Quality Ecosystem Development at 2023 Taihu Bay Life Health Future Conference

TogetherThe Path to High-Quality Development of the Ecosystem

WuxiMay 18, 2023PR Newswire -- Today, the "2023 Taihu Bay Future Conference on Life and Health" (hereinafter referred to as the "Taihu Bay Conference") was grandly held in Wuxi, Jiangsu. This conference was hosted by the Wuxi Municipal People's Government and Jiangnan University, and supported by strategic cooperation institutions such as CICC, AstraZeneca, WuXi Biologics, SDIC Capital, Hony Capital, Tigermed, Guanhe Pharmaceuticals, GE Healthcare, Fresenius Kabi Huari, and Luye Group. The conference focused on discussing industry development trends in technology, industry, investment, and policy within the life and health sector, reflecting the global development requirements of life and health. It provided a series of high-level dialogue and cooperation signing platforms, building a collaborative window for leaders of innovative life and health companies in China, academic experts, and investment institutions attending the event. The aim is to accelerate the implementation of innovative achievements and the integration of industry and investment, working together towards the high-quality development path of a healthy innovation ecosystem.

As one of the strategic partners of the conference, AstraZeneca continues to deeply engage in the Taihu Bay Conference this year alongside various partners, conducting in-depth discussions on the high-quality development of the life sciences and healthcare industry. Adhering to the concept of open collaboration, AstraZeneca remains committed to further developing a health innovation ecosystem, continuously expanding its "circle of partners," and, under the long-term goal of high-quality development, accelerating the implementation of innovative outcomes with cross-sector partners from government, industry, academia, research, medicine, and investment, supporting the realization of the "Healthy China 2030" objectives.

Mr. Leon Wang, Executive Vice President of AstraZeneca Global, President of International Business and China, stated during the roundtable dialogue session at the main summit of the conference: "As an annual event in the life and health sector in Jiangsu and across China, Taihu Bay Conference is committed to providing a significant platform for expanding the innovative ecosystem, investment and financing cooperation, and technical exchanges in the life and health industry, accelerating the high-quality development of China's life and health industry. As a strategic partner of the conference, AstraZeneca will also leverage the momentum of the Taihu Bay Conference platform to collaborate with all parties in the healthcare innovation ecosystem to continuously advance the construction of the ecosystem and jointly promote the high-quality development of the medical industry. Not only that, this year marks the 30th anniversary of AstraZeneca's entry into China, and the remarkable journey of AstraZeneca China over these three decades originated right here in Wuxi. Over the past thirty years, while being rooted in Wuxi, we have fully supported and witnessed the rapid development of the local life and health industry. In the future, AstraZeneca will continue to deeply explore the path of high-quality development through the integration of industry and finance in the life and health sector, grasp the cutting-edge innovative trends in the domestic and international industries, and believe that with the strong support of the Wuxi municipal government and the joint efforts of all parties, AstraZeneca will take Wuxi as a starting point to bring more fruitful results of innovative ecosystems to China and even the world."

Leo Wang, Executive Vice President of AstraZeneca Global, President of International Business and China, Participated in the Roundtable Dialogue at the Main Summit of the Conference

This Taihu Bay Conference also hosted a series of parallel activities. Among them, Mr. Leon Lai, General Manager of AstraZeneca China, stated in his keynote speech at the CICC Investment and Financing Forum: "On the basis of strategic planning and business market development, AstraZeneca also highly values the establishment of an open, cooperative, and win-win innovative ecosystem, promoting cross-sector collaboration with government, industry, academia, research, medical, and investment parties. Notably, as a remarkable outcome of cooperation between industry and finance, the AstraZeneca-CICC Healthcare Industry Fund will continue to support the cultivation and upgrading of locally innovative medical achievements in China, ultimately helping Chinese innovations benefit patients in China and even globally."

Mr. Minglong Lai, General Manager of AstraZeneca China, Delivers Keynote Speech at CICC Investment and Financing Forum

In addition, the conference held a dialogue meeting between enterprises and the government on the topic of deepening public-private cooperation. AstraZeneca, along with medical innovation companies such as Ancel Biotech, Auransa Bioscience, and Zhi Zhong Medical, attended the meeting and engaged in in-depth exchanges.

As a key event in the Taihu Bay Conference series, the "6th AstraZeneca China Ecosystem Conference and AstraZeneca China 30th Anniversary Celebration" will be officially held on May 19. With the theme of "Harmony and Co-prosperity," this ecosystem conference will bring together thousands of industry participants from the life sciences and healthcare sectors both within and outside China.TopExperts and leaders, high-growth companies, technical specialists, professional investors, and other industry partners attended. Discussions were held on the localization development of multinational enterprises in China, government-enterprise cooperation, cross-sector ecosystem empowerment focusing on metabolism/respiratory/oncology/rare diseases, digital healthcare, industry-finance integration, international cooperation, and other hot topics within the industry. Forward-looking and authoritative exchange dialogues were conducted. The formal release of significant landing achievements of the innovative ecosystem included the "Wuxi Standardized Management System for Metabolic Diseases Citywide Model," sharing experiences in the high-quality development of the industry.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a science-led global biopharmaceutical business focused on the discovery, development, and commercialization of prescription medicines, primarily in Oncology, Rare Diseases, and including Cardiovascular, Renal & Metabolism, Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries worldwide, delivering innovative medicines to millions of patients globally. For more information, please visitwww.astrazeneca.com。

About AstraZeneca China

Since entering China in 1993, AstraZeneca has focused on the treatment areas with the most urgent needs for Chinese patients, including oncology, cardiovascular, metabolic, renal, respiratory, gastroenterology, vaccines and antibodies, autoimmune diseases, and rare diseases, bringing nearly 40 innovative drugs to China. The company’s China headquarters is located in Shanghai, with regional headquarters in Beijing, Guangzhou, Hangzhou, Chengdu, Wuxi, and Qingdao. The production base and logistics center established in China have exported medicines to nearly 70 countries and regions worldwide. Today, China has become AstraZeneca's second-largest market globally.